Literature DB >> 18945780

Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer.

Alan L Parker1, Simon N Waddington, Suzanne M K Buckley, Jerome Custers, Menzo J E Havenga, Nico van Rooijen, Jaap Goudsmit, John H McVey, Stuart A Nicklin, Andrew H Baker.   

Abstract

The deployment of adenovirus serotype 5 (Ad5)-based vectors is hampered by preexisting immunity. When such vectors are delivered intravenously, hepatocyte transduction is mediated by the hexon-coagulation factor X (FX) interaction. Here, we demonstrate that human sera efficiently block FX-mediated cellular binding and transduction of Ad5-based vectors in vitro. Neutralizing activity correlated well with the ability to inhibit Ad5-mediated liver transduction, suggesting that prescreening patient sera in this manner accurately predicts the efficacy of Ad5-based gene therapies. Neutralization in vitro can be partially bypassed by pseudotyping with Ad45 fiber protein, indicating that a proportion of neutralizing antibodies are directed against the Ad5 fiber.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18945780      PMCID： PMC2612319          DOI： 10.1128/JVI.01878-08

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  30 in total

1.  Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.

Authors:  Diane M Roberts; Anjali Nanda; Menzo J E Havenga; Peter Abbink; Diana M Lynch; Bonnie A Ewald; Jinyan Liu; Anna R Thorner; Patricia E Swanson; Darci A Gorgone; Michelle A Lifton; Angelique A C Lemckert; Lennart Holterman; Bing Chen; Athmanundh Dilraj; Angela Carville; Keith G Mansfield; Jaap Goudsmit; Dan H Barouch
Journal:  Nature       Date:  2006-04-16       Impact factor: 49.962

2.  Structure-based identification of a major neutralizing site in an adenovirus hexon.

Authors:  Susan L Pichla-Gollon; Mark Drinker; Xiangyang Zhou; Feng Xue; John J Rux; Guang-Ping Gao; James M Wilson; Hildegund C J Ertl; Roger M Burnett; Jeffrey M Bergelson
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

3.  Coagulation factor X-binding protein from Deinagkistrodon acutus venom is a Gla domain-binding protein.

Authors:  H Atoda; M Ishikawa; H Mizuno; T Morita
Journal:  Biochemistry       Date:  1998-12-15       Impact factor: 3.162

4.  Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.

Authors:  Shawn M Sumida; Diana M Truitt; Angelique A C Lemckert; Ronald Vogels; Jerome H H V Custers; Marylyn M Addo; Shahin Lockman; Trevor Peter; Fred W Peyerl; Michael G Kishko; Shawn S Jackson; Darci A Gorgone; Michelle A Lifton; Myron Essex; Bruce D Walker; Jaap Goudsmit; Menzo J E Havenga; Dan H Barouch
Journal:  J Immunol       Date:  2005-06-01       Impact factor: 5.422

5.  Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity.

Authors:  Dmitry M Shayakhmetov; Anuj Gaggar; Shaoheng Ni; Zong-Yi Li; André Lieber
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

6.  Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo.

Authors:  O Kalyuzhniy; N C Di Paolo; M Silvestry; S E Hofherr; M A Barry; P L Stewart; D M Shayakhmetov
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-07       Impact factor: 11.205

7.  Adenovirus serotype 5 hexon mediates liver gene transfer.

Authors:  Simon N Waddington; John H McVey; David Bhella; Alan L Parker; Kristeen Barker; Hideko Atoda; Rebecca Pink; Suzanne M K Buckley; Jenny A Greig; Laura Denby; Jerome Custers; Takashi Morita; Ivo M B Francischetti; Robson Q Monteiro; Dan H Barouch; Nico van Rooijen; Claudio Napoli; Menzo J E Havenga; Stuart A Nicklin; Andrew H Baker
Journal:  Cell       Date:  2008-02-08       Impact factor: 41.582

8.  Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D.

Authors:  Alan L Parker; John H McVey; Jessica H Doctor; Oscar Lopez-Franco; Simon N Waddington; Menzo J E Havenga; Stuart A Nicklin; Andrew H Baker
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

9.  Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes.

Authors:  Alan L Parker; Simon N Waddington; Campbell G Nicol; Dmitry M Shayakhmetov; Suzanne M Buckley; Laura Denby; Geoffrey Kemball-Cook; Shaoheng Ni; Andre Lieber; John H McVey; Stuart A Nicklin; Andrew H Baker
Journal:  Blood       Date:  2006-06-20       Impact factor: 22.113

10.  Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5.

Authors:  Simon N Waddington; Alan L Parker; Menzo Havenga; Stuart A Nicklin; Suzanne M K Buckley; John H McVey; Andrew H Baker
Journal:  J Virol       Date:  2007-06-06       Impact factor: 5.103
View more
  40 in total

1.  Optimized adenovirus-antibody complexes stimulate strong cellular and humoral immune responses against an encoded antigen in naive mice and those with preexisting immunity.

Authors:  Jin Huk Choi; Joe Dekker; Stephen C Schafer; Jobby John; Craig E Whitfill; Christopher S Petty; Eid E Haddad; Maria A Croyle
Journal:  Clin Vaccine Immunol       Date:  2011-11-16

2.  Integrase-deficient lentiviral vectors mediate efficient gene transfer to human vascular smooth muscle cells with minimal genotoxic risk.

Authors:  Helen E Chick; Ali Nowrouzi; Raffaele Fronza; Robert A McDonald; Nicole M Kane; Raul Alba; Christian Delles; William C Sessa; Manfred Schmidt; Adrian J Thrasher; Andrew H Baker
Journal:  Hum Gene Ther       Date:  2012-10-26       Impact factor: 5.695

Review 3.  A novel fiber chimeric conditionally replicative adenovirus-Ad5/F35 for tumor therapy.

Authors:  Ming Yang; Chun Sheng Yang; WenWen Guo; JianQin Tang; Qian Huang; ShouXin Feng; AiJun Jiang; XiFeng Xu; Guan Jiang; Yan Qun Liu
Journal:  Cancer Biol Ther       Date:  2017-11-16       Impact factor: 4.742

4.  Recent advances of oncolytic virus in cancer therapy.

Authors:  Moumita Mondal; Jingao Guo; Ping He; Dongming Zhou
Journal:  Hum Vaccin Immunother       Date:  2020-02-20       Impact factor: 3.452

5.  In vitro functional testing of endothelial progenitor cells that overexpress thrombomodulin.

Authors:  John D Stroncek; Yujing Xue; Nabila Haque; Jeffrey H Lawson; William M Reichert
Journal:  Tissue Eng Part A       Date:  2011-05-25       Impact factor: 3.845

6.  Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors.

Authors:  Jenny A Greig; Suzanne Mk Buckley; Simon N Waddington; Alan L Parker; David Bhella; Rebecca Pink; Ahad A Rahim; Takashi Morita; Stuart A Nicklin; John H McVey; Andrew H Baker
Journal:  Mol Ther       Date:  2009-07-14       Impact factor: 11.454

Review 7.  Circumventing antivector immunity: potential use of nonhuman adenoviral vectors.

Authors:  Estrella Lopez-Gordo; Iva I Podgorski; Nicholas Downes; Ramon Alemany
Journal:  Hum Gene Ther       Date:  2014-03-25       Impact factor: 5.695

8.  Cell entry and trafficking of human adenovirus bound to blood factor X is determined by the fiber serotype and not hexon:heparan sulfate interaction.

Authors:  Stéphanie Corjon; Gaëlle Gonzalez; Petra Henning; Alexei Grichine; Leif Lindholm; Pierre Boulanger; Pascal Fender; Saw-See Hong
Journal:  PLoS One       Date:  2011-05-26       Impact factor: 3.240

9.  Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery.

Authors:  Lynda Coughlan; Angela C Bradshaw; Alan L Parker; Hollie Robinson; Katie White; Jerome Custers; Jaap Goudsmit; Nico Van Roijen; Dan H Barouch; Stuart A Nicklin; Andrew H Baker
Journal:  Mol Ther       Date:  2012-08-28       Impact factor: 11.454

Review 10.  Gene Therapies for Cancer: Strategies, Challenges and Successes.

Authors:  Swadesh K Das; Mitchell E Menezes; Shilpa Bhatia; Xiang-Yang Wang; Luni Emdad; Devanand Sarkar; Paul B Fisher
Journal:  J Cell Physiol       Date:  2015-02       Impact factor: 6.384
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.